Diana lai’s testimony at fda public hearing on benlysta

Diana lai\’s testimony at fda public hearing on benlysta

On November 16, 2010 the FDA held hearings to discuss BENLYSTA, sponsored by Human Genome Sciences, for the proposed indication of reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE). Petra Harvey speaks on behalf of Eva Gaskins. Click bit.ly to access transcript of testimony from Eva Gaskins, Member of the Lupus Foundation of America, DC-MD-VA Chapter….



Diana lai\’s testimony at fda public hearing on benlysta